A gated material as immunosensor for in-tissue detection of IDH1-R132H mutation in gliomas

[Display omitted] •The presence of IDH1-R132H mutated enzyme in gliomas has been related to a better prognosis.•Here is reported a nanodevice for the detection of IDH1-R132H mutant enzyme in human glioma tissue.•The nanodevice is based on NAA supports functionalized with antibody-based gatekeepers.•This nanodevice shows good sensitivity (LOD 0.01 ng/mL) and selectivity.•In glioma tissue it shows sensitivity/specificity for IDH1-R132H mutational status of 87.5/88.9. A nanodevice consisted on nanoporous anodic alumina (NAA) supports functionalized with specific and selective antibody-based gatekeepers for the detection of IDH1-R132H mutant enzyme is here reported. Molecular profile and tissue mutations of the tumours (such as IDH1/IDH2 mutations in gliomas) are a great source of information that already make a difference in terms of prognosis and prediction of response to combined therapy. However, standardized methodologies to determine this mutation are time-consuming and cannot provide information before or during surgical intervention, which significantly limits their utility in terms of intraoperative decision-making. To solve this limitation, our sensing system, in the presence of the target IDH1-R132H mutant enzyme triggers the delivery of a fluorescent reporter from the antibody-capped NAA that is easily detected using a standard fluorimeter in less than 1 h. Good capabilities of the sensor in terms of sensitivity (limit of detection as low as 0.01 ng/mL) and selectivity are determined. The biosensor is validated in seventeen human glioma tissue samples, also analysed by standardized methodologies, showing significant differences between IDH1 wild-type and IDH1-R132H mutant gliomas (p